Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Lowered by StockNews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Other analysts have also issued reports about the stock. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday. HC Wainwright increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, Stephens assumed coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $32.86.

Catalyst Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ CPRX opened at $21.92 on Friday. Catalyst Pharmaceuticals has a 52-week low of $13.12 and a 52-week high of $24.27. The business’s 50 day moving average is $21.77 and its two-hundred day moving average is $19.90. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 3.35 and a beta of 0.79.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC purchased a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $50,000. Larson Financial Group LLC increased its stake in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth about $70,000. Finally, Quantbot Technologies LP acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at about $151,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.